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The promise of idiotype-based therapeutics has been disappointing forcing a new look at
the concept and its potential to generate an effective approach for immunotherapy. Here,
the idiotype network theory is revisited with regard to the development of efficacious
anti-idiotype vaccines. The experience of polyclonal anti-Idiotype reagents in animal
models as well as an understanding of the immune response in humans lends to
the proposition that polyclonal anti-Idiotype vaccines will be more effective compared
to monoclonal-based anti-Idiotype vaccines. This novel strategy can be adapted in
Biotech-standard production of therapeutic antibodies.
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1. INTRODUCTION
The strategy of using anti-idiotype (anti-Id) antibodies as surrogate antigens stems from the
Idiotype cascade proposed by Niels Jerne (1). Accordingly, anti-Id antibodies were originally
described as Ab2α and Ab2β, whereby the former does not block antigen binding and the latter
can inhibit binding of the corresponding Ab1 to its antigen. This lent to the conclusion that Ab2β
mimics structurally the antigen for Ab1. The concept and its experimental use have been extensively
reviewed, (2–5). Noted advantages of using anti-Ids over nominal antigens as therapeutic vaccines
include difficulties to produce vaccines containing non-protein antigens. Anti-Ids can be produced
that mimic lipid, carbohydrate or nucleic acid epitopes or even drugs. Tolerance to antigens is a
major hurdle in vaccine development. Antibody-B Cell Receptor binding occurs at multiple sites,
while antigen strictly binds to Complementary Determining Regions (CDRs) of antibodies. This
allows stimulation of a broader determinate targeting antibody response that might include epitope
spreading. Finally, anti-Ids can be persistent in inducing an immune response against antigens
while avoiding autoimmune responses triggered by nominal antigen based vaccines (6).
A major obstacle both theoretically and practically is reconciling the immunization concept
with the postulated restriction of the putative idiotypic network of natural antibody producing
B cell clones (7). Natural antibodies, in the strictest sense, are constitutively produced (8), but
this strict definition leaves out some polyreactive antibodies induced in marginal zone B cells and
in T-cell independent responses, which can also be defined as natural antibodies in a broader
sense (9–11). The gray zone of the natural antibody concept probably contains the answers to
some of the paradoxes of idiotypy. Thus, several animal studies using anti-Id antibodies support
their utility, as vaccines while human trials with monoclonal Ab2β were disappointing and have
failed in later phase trials. Here, we analyze this failure and propose an alternative strategy for an
idiotype-based immunotherapy.
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2. SETTING THE STAGE FOR THE
IDIOTYPE INTERACTIONS IN
REGULATING AN IMMUNE RESPONSE
In 1963 two laboratories reported evidence for a new marker
on antibodies distinct from allotypes (12, 13). The term
IDIOTYPE for determinants recognized by antibodies was
adopted. Recognizing that antibodies against antibodies exist and
playing a number game on the multitude of B-cells producing
antibodies, Jerne concluded that there must be a functional
network of idiotype (Id) and anti-idiotypes (anti-Id) (14). Thus,
the idiotype network hypothesis was born. Yet, evidence was
lacking for network interactions during an induced immune
response and that an anti-Id response might have a regulating
function. In 1972 several reports appeared on the potential of
anti-Id antibodies to suppress a specific immune response (15–
17). Such results suggested that anti-Ids can affect an immune
response, but did not establish that immune-modulation is part
of an antigen-induced immune response. Two reports supported
this latter premise (17, 18). An idiotypic cascade was perceived:
Ab1>Ab2β >Ab3. Ab3 would resemble Ab1 and were labeled
Ab1’. Jerne distinguished two types of anti-Ids (1, 14): Based on
this concept, Ab2β’s resemble structurally the antigen; thus the
term Internal Image of antigen emerged as an explanation for
this mimicry.
Shortly after this concept emerged several laboratories put this
to the test by using Ab2β as antigen to induce target-specific
immune responses (19–23). The dual functional property of Ab2
was demonstrated as either suppression (15) or induction of a
specific response (24) to be dependent on the IgG-class (25). The
idiotypic cascade implies that Ab1 used therapeutically might
induce an antigen specific antibody response (26). Clinically,
support for the idiotypic cascade is suggested in that patients
developing low-level Human Anti-Mouse Antibody (HAMA)
to a GD2 reactive Ab1 were shown to have higher long-
term survival rates than those who did not (27, 28). GD2 is
a disialoganglioside expressed on tumors of neuroectodermal
origin, including human neuroblastoma and melanoma, with
highly restricted expression on normal tissues, principally to
the cerebellum and peripheral nerves in humans. The relatively
tumor specific expression of GD2 makes it a suitable target for
monoclonal antibody therapy and potentially a proving ground
to probe and dissect network interactions.
The idiotype cascade has been suggested to be part of the
functional utility of at least one monoclonal antibody presently
approved by the US FDA [dinutuximab targeting the GD2
antigen: (29)]. The FDA approved Dinutuximab (Ch14.18, trade
name Unituxin) and Dinutuximab beta (trade name Isquette),
a monoclonal antibody used as a second-line treatment for
children with high-risk neuroblastoma. However, differences in
immune responses to Ab1 might be attributed to differences
in Germline origins of the selected monoclonal Ab1 used
in therapeutic application. A clinical trial with Ch14.18, a
chimeric, in combination with IL-2, while showing a strong
activation of antibody effector functions, did not show a better
clinical outcome (30). Development of human anti-chimeric
antibody (HACA) (21% of patients) did result in strong
reduction of ch14.18 levels, abrogating complement dependent
cytotoxicity and antibody dependent cellular cytotoxicity (31).
The monoclonal studied in Cheung et al. (27, 28) is of the
IGVH2-9∗02 germline while the ch14.18 variable region is
derived from the IGHV1S135∗01 germ line. Little attention is
paid to such difference yet we know that no two antibodies need
to be alike immunologically.
3. LESSONS LEARNED FROM
THERAPEUTIC ANTI-ID ANTIBODIES
While the earlier anti-Id data were generated with polyclonal
antibodies, later experiments used monoclonal anti-Ids
(32, 33). The successful use of monoclonal anti-Ids as
vaccines in inbred mice prompted several clinical trials
with monoclonal Ab2β antibodies. The early studies on the
immunomodulatory activities of Ab2, while consistently
demonstrating immunological activity in animals, clinical trials
with anti-Ids in the cancer space proved to be mixed (34).
Herlyn and coworkers demonstrated that humoral immune
reactivity against a tumor can be enhanced upon active anti-id
vaccination (35). In these studies 30 patients with advanced
colorectal carcinoma (CRC) were treated with alum-precipitated
polyclonal goat anti-Id antibodies to monoclonal anti-CRC
antibody CO17-1A (Ab1) in doses between 0.5 and 4mg per
injection. All patients developed Ab3 with binding specificities
on the surface of cultured tumor cells similar to the specificity
of Ab1. Furthermore, the Ab3 competed with Ab1 for binding
to CRC cells. Fractions of Ab3-containing sera obtained after
elution of the serum immunoglobulin from CRC cells bound
to purified tumor antigen and inhibited binding of Ab2 to Ab1.
Six patients showed partial clinical remission and seven patients
showed arrest of metastases following immunotherapy (35).
Therefore, it was concluded that the Ab3 could share binding
similarities with Ab1.
In other studies, an anti-Id vaccine to induce anti-
Carcinoembryonic antigen (CEA) antibodies (Ab3) was tested
in non-human primates (36). CEA is a tumor marker largely
utilized for the detection of minimal disease associated with
colon cancer and considered a target for immunotherapy. The
murine monoclonal antibody specific for CEA, was generated via
hybridoma technology and selected for inhibition of the binding
to CEA. These successful preclinical studies led to clinical trials
in humans with CEA positive tumors (37). In this trial, 9 of 12
patients demonstrated an anti-anti-idiotypic (Ab3) response. All
nine patients generated specific anti-CEA antibody demonstrated
by reactivity with radiolabeled purified CEA. Toxicity was limited
to local reaction with mild fever and chills. However, in all
12 patients the tumor progressed after completion of the trial.
Four of seven responding patients were reported to have T cell
responses to purified CEA suggesting that there was an antigen
specific T cell response after immunization (37). A patent was
filed for the anti-Id (Chatterjee et al. 5,977,315). Yet, a phase II
trial with anti-Id did not improve relapse of tumor (38) and a
phase III study with the anti-Id and 5-Fluorouracil (5-FU) did
not improve the overall outcome of the study (39). In preclinical
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models CEA was found to be up-regulated after exposure of
cancer cells to 5-FU (40). Therefore, the premise for combination
therapy would be to increase the expression of the target antigen
for Ab3 to bind to.
Further anti-Id-based vaccine studies in humans have
included those associated with Tumor Associated Carbohydrate
Antigens (TACAs), particularly the ganglioside targets GD3 and
GD2. The anti-Id BEC2, a mimic for GD3, was found not
to be highly immunogenic in melanoma patients suggesting
adjuvants might be necessary (41–43). More recently BEC2
was considered as a therapeutic intervention in GBS by
neutralizing specific pathogenic anti-ganglioside antibodies (44).
The murine monoclonal anti-Id antibody 1A7 (TriGem), a
mimic of GD2, has been tested in pre-clinical studies and in
the clinic (45). In pre-clinical studies, active immunization of
mice, rabbits, and monkeys with TriGem induced polyclonal
IgG anti-GD2 responses and TriGem specific T cell proliferative
responses suggesting the generation of CD4+ T cell help. In
clinical trials, it was demonstrated that patients with advanced
metastatic melanoma and patients with high-risk melanoma
in the postsurgical adjuvant setting generated active immune
responses against GD2 following immunization with TriGem.
IgG subclasses were shown to be predominately IgG1 and IgG4,
suggesting the possibility of the generation of CD4+ T cell help.
Median survival was 16+ months for 47 patients with advanced
disease. Eighty-two percent of 69 patients with stage III disease
were alive at a median follow up of 2 years.
An anti-Id vaccine has reached the market. Racotumomab
(Vaxira) is now the first approved anti-Id vaccine—with approval
in Cuba and Argentina. Vaxira was shown to increase the
survival of Non-Small Cell Lung Cancer patients in recurrent or
advanced stages (IIIB/IV). A phase III trial is currently ongoing
(NCT01460472). The vaccine was initiated by the Center for
Molecular Immunology in Havana, Cuba. Racotumomab, an
Ab2γ, was raised against the murine anti-ganglioside N-glycolyl
(NGc) GM3 (NGcGM3) (46). The safety of Racotumomab was
established in several phase I trials in melanoma, breast and lung
cancers (47, 48). In the lung trial, patients developed antibodies
against NGcGM3 and had longer medium survival times (49).
Results from a randomized trial with Racotumomab showed
necrosis of tumor cells as a mechanism for efficacy (50).
While preclinical studies suggested that anti-Ids could
mediate cellular responses, little evidence in humans
demonstrates this aspect (51, 52). The most direct example
for the activation of CD8+ Cytotoxic T Lymphocytes (CTL)
involvement comes from a clinical trial testing a combination of
the murine anti-id monoclonal antibodies MEL-2 and MF11–30
that are mimics of the high molecular weight melanoma-
associated antigen (HMW-MAA) (53). The two anti-ids mimic
two distinct epitopes of HMW-MAA. This combination called
MELIMMUNE was shown to induce HLA-A2-restricted CTLs
that lyse melanoma cells expressing both HLA-A2 antigen and
HMW-MAA (53). Collectively, preclinical and clinical trials,
albeit very limited, indicate that anti-Id vaccines can induce B
and T-cell immune responses both in general terms supporting
CD4+ T cell activation for IgG production and tumor antigen
specific CD8+ CTLs if the anti-Ids are properly chosen.
4. SOLVING THE PROBLEMS WITH
CURRENT ANTI-ID VACCINES
While showing promise, to date no anti-Id-based vaccines
has been approved by the US FDA for use in patients.
Reasons for the failure of anti-Id vaccines against tumors
are similar to generalized failures of other cancer vaccines.
On the one hand it is possible that such failures reflect the
patient populations used in the studies. We have now come
to realize that checkpoint inhibitors are necessary to take the
brakes off the immune system. On the other hand a major
problem in cancer is the complexity and heterogeneity of antigen
expression, the antigens that are potential targets of T and B-
cells are multiple, diverse and endlessly adaptable. This reduces
the ability of responding immune cells to consistently carry
out their task to recognize, bind and destroy. A lesson might
be forthcoming from consideration of the “normal” immune
response to pathogens as many viruses, bacteria, and parasites
induce a strong polyclonal B cell response, which can be crucial
for early host defense against rapidly dividing microorganisms.
In certain situations the response is restricted such as in
HIV infections (54, 55). Interestingly, this clonal-restricted
antibody response shares an idiotypic marker (56), termed
Ab2δ. The polyclonal and sometimes oligoclonal antibodies in
immune reactions would suggest that, in order to stimulate
the polyclonal Ab1 spectrum, Ab2 should also be polyclonal.
Early vaccine experiments were performed in rabbits and not
subject to potential monoclonal anti-Id restrictions (25, 57).
Later experiments suggested a strategy to simulate polyclonal
immunization by combining monoclonals that are functional
anti-Ids in that they compete with antigen clearly are not
distinguished in their ability to activate functional T cell
responses a priori (53, 58, 59). Yet making a panel of hybridomas
by screening and selecting only high affinity binders may not
be enough to distinguish between protective and non-protective
anti-Ids (59).
The advantages of polyclonal vs. monoclonal antibodies
has recently been reviewed (60). Previous discussions have
suggested a soluble antigen reflective of multiple epitopes can
be a more potent modulator of humoral and cellular immune
responses than Ab2 that represents a singular epitope (61).
Counter arguments have been made (62). However, these
arguments often neglect a possible influence of a network
and the structural basis for antibody recognition. The major
characteristic of polyclonal responses is their clonal and
structural diversity. Multi-epitope binding increases the overall
avidity to the target. For optimizing the targeting of Ab2 to
idiotype expressing B-cell receptors all classes of anti-Id, (Ab2α,
Ab2β, Ab2γ, and Ab2δ) should be involved. Thus, a polyclonal
or oligoclonal anti-Id vaccine would improve targeting, by
invoking a “normal’ polyclonal immune response. Polyclonal
B cell response is a natural mode of an immune response in
adaptive immunity. It is a practical and functionally important
element of a healthy immune system, with considerable
evidence to support its role in protection from at the least
infectious agents. Consequently, we are proposing to change
the strategy of monoclonal-based anti-Id vaccine development
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and use. Immunizing with polyclonal–based anti-Ids has the
capacity to induce humoral antigen spread in patients by
engaging multiple BCR’s with the potential to activate both
targeted and non-targeted antibody producing B and T
cells. Immunizations with selected polyclonal anti-Ids to one
or multiple target antigens might be a plausible strategy
to amplify preexisting B cells and potentially preexisting
T cell responses in addition to de novo generation of
novel responses. This strategy abandons the concept that
the idiotype vaccine represents the “Internal Image” of
the antigen and supports our earlier suggestion of being
a “Network Antigen” (63).
5. RECIPES FOR MAKING POLYCLONAL
ANTI-ID-BASED VACCINES
A key prerequisite for an idiotypic network is poly/autoreactivity
of some B cell clones. Moreover, it implies positive selection
on existing variable regions for which there is evidence (64–
66). Positive selection of the B cell repertoire has been
demonstrated numerous times over a span of years (67–71)
but the nature and the intensity of the self-signal define the
choice between elimination, annergy and survival. This implies
that a certain range of signal intensities including from existing
antibody variable regions can probably recruit the emergent
repertoire (7). A constant component of natural IgM would
provide the necessary signal exposing idiotopes in the CDR3
regions (72), albeit other regions can be defined as idiotope
containing (73), of the required concentration. The unique
structures would be too dilute but those shared by a number
of clones or sets of clonal products recognized cross-reactively
by the same paratope would provide signal sufficient either
for positive selection or for negative if the signal were too
strong. Maybe this precludes the selection by too broadly
distributed public idiotopes. It is interesting to speculate that
every strong antibody response might temporarily provide a
similar signal. During this time of optimal intensity it may
recruit corresponding anti-idiotypic immature B cells. This
mechanism may constitute an indirect way to elicit anti-Ids
by (inadvertently) manipulating the existing natural antibody
network and its capacity to recruit anti-Ids. It may reconcile
the “second generation” network concept (7) with experimental
induction of anti-Ids as well as introduce the notion that a set of
clones rather than a single antibody may be necessary to put this
machine in motion.
To stimulate and simulate a polyclonal response, Ab2s can
be a mixture of monoclonal antibodies stimulating B and T-
cells (53, 58). There are examples of anti-Ids containing both
B and T cell epitopes (59, 74). Admixing them might broaden
a response. An alternative concept of inducing antibodies
against multiple tumor-associated antigens is a pan-immunogen,
which harbors “fuzzy” mimicking determinants to induce a
polyclonal response to multiple antigens. This concept has
not been developed with an Ab2-based vaccine but antigen-
mimicking peptides of glycans and TACA have shown such
an ability in preclinical (75–80) and clinical studies (81, 82)
where a carbohydrate mimetic peptide can induce polyclonal
responses to two or more TACAs (81–83). This can be due
both to shared epitopes as well as to a multifaceted mimotope
exposing diverse antigenic determinants—a structural substrate
of immunological polyspecificity.
The advantage of monoclonal antibodies over polyclonal
is its consistency and excellent characterization. Monoclonals
are produced by cell cultures seeded from a reference
cell bank. In contrast polyclonal antibodies are derived
from immunized animals producing a unique batch-specific
biochemical and biophysical property. For use in humans,
each batch must be validated satisfying the advertised criteria.
The call for polyclonal or oligoclonal anti-Id antibodies
must be answered with novel production strategies. The
final step in monoclonal antibody production by hybridoma
or recombinant technologies is the selection of the most
potent clone or cell line. This is performed under so-
called limiting dilution conditions. Suppose one reduced the
stringency of selection and mixed a number of clones including
ones with lower affinity. The number of antibodies in this
polyclonal mix can be controlled. A master cell bank can
be established, similar to the master banks in monoclonal
production. However, since there is no experience with the
clonal stability of cell lines growing in large cell culture
tanks research will be required to maintain the original cell
culture mix.
COVERED IN THIS REVIEW
1. Rationale and strategy of idiotype-based
vaccines-Sections 1-5.
2. Ab1 can also be used to initiate idiotype cascades - Section 2.
3. Lessons learned - Section 3
a. Ab3 can share binding similarities with Ab1
b. Utility in combination therapy
c. Clinically, Anti-Ids can induce B and T-cell immune
responses against antigens.
4. Rational for importance of polyclonal responses - Section 4.
5. Redefining the mimetic nature of anti-Ids as network
antigens - Section 4.
6. Introduction of a Master Bank for Polyclonal
anti-Ids - Section 5.
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